Key Takeaways
- Calysta raised a new round.
- Sector: Agriculture, Agribusiness & Agtech, Biotechnology & Life Sciences, Cleantech & Climatech.
- Geography: China, Ghana, United States.
Analysis
Calysta, a pioneer in methane-based single-cell protein production, has appointed Berend Jan Kingma as its new Chief Executive Officer. This leadership transition coincides with an urgent drive to secure fresh capital, following the cessation of financial backing from its joint venture partner in China.
The company's demonstration-scale facility in Chongqing, operated under the Calysseo joint venture with animal nutrition firm Adisseo, has temporarily halted operations. The pause is attributed to a critical need for substantial investment to finalize essential technical upgrades and ensure the facility's ongoing viability. Adisseo, in a recent regulatory filing, confirmed its decision not to extend financial support, citing the inherent complexities and scale-up challenges within the biotechnology sector, alongside difficulties in securing external funding for the venture.
Kingma, who joined Calysta on July 1st, brings a wealth of experience from leadership roles in capital-intensive, emerging market businesses. His background includes steering agrifood scale-ups like InspiraFarms and FirstWave Group, as well as managing the FrieslandCampina China joint venture. His prior experience at McKinsey and as CEO of Miro Forestry in Ghana further underscores his expertise in operational scaling and strategic financial management.
The financial situation at Calysseo highlights the demanding nature of scaling novel protein production. Unaudited 2025 figures reveal total assets of $78.7 million against liabilities of $63.9 million, with revenues of $710,000 and a net loss of $15.5 million. This underscores the significant working capital deficit that necessitates immediate funding to resume production and address economic viability challenges within the competitive feed substitute protein market.
Despite these hurdles, Calysta co-founder Alan Shaw PhD, now non-executive chair, emphasized the ongoing focus on optimizing downstream processing to enhance throughput and reduce production costs. The company has successfully demonstrated its gas fermentation technology, producing thousands of tons of its FeedKind protein for the aquafeed market since receiving Chinese government approval in 2024. Strong local demand, driven by high fishmeal prices, validates the market's need for sustainable protein alternatives.
The company is also anticipating approval for its FeedKind product in the Chinese petfood market by Q3 2026, with significant commercial interest from European petfood brands. This strategic pivot from a technology developer to a market-ready protein supplier underscores the potential of gas fermentation, a field that has seen both innovation and consolidation, with companies like Novonutrients and Arkeon ceasing operations while others, such as Denmark's Unibio and Finland's Solar Foods, pursue ambitious commercialization plans.